Back to top
more

ARK Genomic Revolution ETF: (ARKG)

(Real Time Quote from BATS) As of Nov 19, 2026 01:02 PM ET

$41.08 USD

41.08
2,360,397

-0.18 (-0.44%)

Volume: 2,360,397

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

NA

Zacks News

Neena Mishra headshot

A Deep Dive into ARK ETFs

We highlight the best performing ETFs managed by Cathie Wood

Sanghamitra Saha headshot

Space ETFs Soar on ARK Investment Management's Filing

Procure Space ETF (UFO) jumped 5.7% on Jan 14 as Cathie Wood's ARK Investment Management filed for a space ETF.

Sweta Killa headshot

Power-packed ETFs for Your Portfolio in 2021

We have highlighted a pack of ETFs that are poised to outperform in 2021.

Sweta Jaiswal, FRM headshot

5 Top-Performing ARK ETFs Worth Your Attention Now

Here we highlight some ETFs from the house of ARK Investment Management that have gained more than 100% in the past year for our investors to consider.

Sweta Jaiswal, FRM headshot

A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

Neena Mishra headshot

ETF Market Outlook & Picks for 2021

Two ETF experts share their market outlook and top picks for 2021.

Neena Mishra headshot

Top Performing ETF Areas of 2020

We highlight some ETFs that more than doubled in 2020

Sweta Killa headshot

4 Best Performing Sector ETFs of December

Despite the surge in coronavirus cases, December has been kind for the U.S. stock market with the major indices enjoying a historic rally.

Sweta Killa headshot

Top & Flop Zones of 2020 and Their ETFs

We have highlighted the best and worst-performing zones and their ETFs in 2020.

Sweta Jaiswal, FRM headshot

Top-Performing Biotech ETFs Amid the COVID-19 Crisis

The coronavirus pandemic triggered a race to introduce vaccine and treatment, thereby opening up new investing opportunities in the biotech sector in 2020.